Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.8.0.1
Consolidated Statements of Comprehensive Loss
₪ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2017
ILS (₪)
₪ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
ILS (₪)
₪ / shares
shares
Dec. 31, 2015
ILS (₪)
₪ / shares
shares
Profit (loss) [Abstract]        
Revenue ₪ 1,668 $ 481 ₪ 292
Cost of Revenue 52 15
Gross Profit 1,616 466 292
Research and development expenses:        
Research and development expenses 16,921 4,881 29,200 22,919
Participation in research and development expenses (2,855) (823) (12,411) (11,055)
Research and development expenses, net 14,066 4,058 16,789 11,864
General, administrative and marketing expenses 8,303 2,394 11,048 6,950
Operating loss 20,753 5,986 27,545 18,814
Financial income (253) (74) (93) (215)
Financial expenses 380 110 441 51
Financial expenses (income), net 127 36 348 (164)
Comprehensive loss ₪ 20,880 $ 6,022 ₪ 27,893 ₪ 18,650
Basic and diluted loss per ordinary share (NIS/USD) | (per share) ₪ 0.16 $ 0.05 ₪ 0.28 ₪ 0.22
Weighted average ordinary shares outstanding 133,187,048 133,187,048 100,624,945 84,672,767